Clinical Trial Update: Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and ability of once-daily glycopyrrolate inhalation solution delivered via an eFlow nebulizer to improve airflow in COPD; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Glycopyrrolate Inhalation Solution (GIS) (glycopyrrolate)

Snippet

Sponsor: Sunovion Respiratory Development Inc. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-03-12